Trials / Completed
CompletedNCT03863860
A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With Fluzoparib Capsules Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 252 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy, safety tolerability of maintenance therapy with Fluzoparib(A PARP inhibitor) versus placebo in Chinese patients with recurrent ovarian cancer who achieved a complete response (CR) or partial response (PR) after platinum-based chemotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluzoparib capsules | Fluzoparib capsules |
| DRUG | Placebo capsules | Placebo capsule |
Timeline
- Start date
- 2019-04-30
- Primary completion
- 2022-01-10
- Completion
- 2025-06-19
- First posted
- 2019-03-05
- Last updated
- 2025-07-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03863860. Inclusion in this directory is not an endorsement.